"2013-10-31+01:00"^^ . . "2009-01-01+01:00"^^ . " flow cytometry" . . "U pacientek s karcinomem endometria a ov\u00E1ria bude stanovena DNA ploidita. U aneuploidn\u00EDch n\u00E1dor\u016F bude zvolena radik\u00E1ln\u011Bj\u0161\u00ED forma terapie v r\u00E1mci doporu\u010Den\u00E9ho postupu. Provedeme anal\u00FDzu v\u00FDsledk\u016F ve vztahu k dal\u0161\u00EDmu pr\u016Fb\u011Bhu onemocn\u011Bn\u00ED." . "V\u00FDznam DNA ploidity a vybran\u00FDch biologick\u00FDch marker\u016F karcinomu endometria nebo ov\u00E1ria pro volbu terapie a ovlivn\u011Bn\u00ED l\u00E9\u010Debn\u00FDch v\u00FDsledk\u016F - prospektivn\u00ED studie." . " endometrial carcinoma" . . "2011-12-31+01:00"^^ . "NS9975" . . . . . "DNA ploidy and selected biological markers value for treatment selection and its impact on clinical outcome in endometrial or ovarian carcinoma - prospective study."@en . . "DNA ploidy; flow cytometry; endometrial carcinoma; ovarian carcinoma"@en . . "DNA ploidy" . . . . . . "http://www.isvav.cz/projectDetail.do?rowId=NS9975"^^ . "1"^^ . . "2011-08-08+02:00"^^ . "1"^^ . . "3"^^ . "Cytometric DNA analysis of endometrial and ovarian carcinoma will be performed using fresh/frozen tissue and standard technique. We will choose more radical therapy in DNA aneuploid tumors. We will perform data analysis in relation to clinical outcome (disease-free survival, overall survival)."@en . "3"^^ . . "0"^^ . "DNA ploidy is suitable prognostic factor for patients with endometrial carcinoma, however multiple examinations are necessary due to its intratumoral heterogenity.There was no correlation found between DNA ploidy and rate survival in ovarian tumors."@en . . "DNA ploidita je vhodn\u00FDm prognostick\u00FDm faktorem u pacientek s karcinomem endometria, je v\u0161ak pot\u0159eba vz\u00EDt v \u00FAvahu jej\u00ED heterogenitu v r\u00E1mci jednoho n\u00E1doru. U n\u00E1dor\u016F ovaria nebyla prok\u00E1z\u00E1na souvislost mezi DNA ploiditou a vznikem recidiv \u010Di p\u0159e\u017Eit\u00EDm."@cs .